Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Multiple Sclerosis ; 16 (2010), 12. - S. 1507-1512. - ISSN 1352-4585. - eISSN 1477-0970
- Keyword
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Event
-
Veröffentlichung
- (where)
-
Konstanz
- (who)
-
Bibliothek der Universität Konstanz
- (when)
-
2014
- Creator
-
Heesen, Christoph
Kleiter, Ingo Wolfram
Nguyen, Franziska
Schäffler, Nina
Kasper, Jürgen
Köpke, Sascha
Gaissmaier, Wolfgang
- URN
-
urn:nbn:de:bsz:352-280329
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.20252025, 1:57 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Heesen, Christoph
- Kleiter, Ingo Wolfram
- Nguyen, Franziska
- Schäffler, Nina
- Kasper, Jürgen
- Köpke, Sascha
- Gaissmaier, Wolfgang
- Bibliothek der Universität Konstanz
Time of origin
- 2014
Other Objects (12)
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
Emergency medical care of multiple sclerosis patients
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
Apheresis therapy in immunopathologically classified multiple sclerosis patients
Multiple sclerosis
Multiple sclerosis
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
Emergency medical care of multiple sclerosis patients
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
Apheresis therapy in immunopathologically classified multiple sclerosis patients
Multiple sclerosis
Multiple sclerosis
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
Patterns of Th1/Th2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate
Emergency medical care of multiple sclerosis patients
Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
Apheresis therapy in immunopathologically classified multiple sclerosis patients
Multiple sclerosis
Multiple sclerosis
Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients